RXRX · Insider Trading
Recursion Pharmaceuticals, Inc. Class A Common Stock
Every open-market purchase and sale reported by RXRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-07 | Blake Borgeson | Director | Sell | −50,000 | −$242.00K |
| 2026-10-07 | Robert Hershberg | Director | MIXED | — | −$69.50K |
| 2026-10-02 | Zavain Dar | Director | A | +4,607 | — |
| 2026-10-02 | Dean Y Li | Director | A | +3,378 | — |
| 2026-09-16 | Ben R Taylor | Chief Financial Officer | F | −5,396 | −$18.40K |
| 2026-09-10 | Najat Khan | CEO and President | Sell | −22,408 | −$78.82K |
| 2026-09-02 | Blake Borgeson | Director | Sell | −30,000 | −$100.20K |
| 2026-08-18 | Ben R Taylor | Chief Financial Officer | F | −25,018 | −$79.06K |
| 2026-08-18 | Najat Khan | CEO and President | F | −80,498 | −$254.37K |
| 2026-08-18 | David Hallett | Chief Scientific Officer | F | −26,657 | −$84.24K |
| 2026-08-06 | Blake Borgeson | Director | Sell | −30,000 | −$97.50K |
| 2026-08-06 | Blake Borgeson | Director | Sell | −30,000 | −$97.50K |
| 2026-07-09 | Blake Borgeson | Director | Sell | −40,000 | −$158.50K |
| 2026-07-02 | Zavain Dar | Director | A | +5,109 | — |
| 2026-07-02 | Dean Y Li | Director | A | +3,747 | — |
| 2026-06-22 | Elaine D Sun | Director | A | +88,424 | — |
| 2026-06-22 | Robert Hershberg | Director | A | +88,424 | — |
| 2026-06-22 | Franziska Michor | Director | A | +88,424 | — |
| 2026-06-22 | Dean Y Li | Director | A | +88,424 | — |
| 2026-06-22 | Blake Borgeson | Director | A | +88,424 | — |
| 2026-06-22 | Zavain Dar | Director | A | +88,424 | — |
| 2026-06-22 | Namandje Bumpus | Director | MIXED | +84,461 | −$12.60K |
| 2026-06-17 | Ben R Taylor | Chief Financial Officer | F | −5,396 | −$17.00K |
| 2026-06-05 | Najat Khan | CEO and President | Sell | −23,588 | −$84.46K |
| 2026-06-05 | Christopher Gibson | Director | MIXED | — | −$144.80K |
| 2026-06-04 | Blake Borgeson | Director | Sell | −30,000 | −$110.40K |
| 2026-06-04 | Namandje Bumpus | Director | Sell | −4,386 | −$15.53K |
| 2026-05-27 | Christopher Gibson | Director | MIXED | — | −$123.20K |
| 2026-05-19 | Ben R Taylor | Chief Financial Officer | F | −25,018 | −$76.05K |
| 2026-05-19 | Najat Khan | CEO and President | F | −62,701 | −$190.61K |
| 2026-05-19 | David Hallett | Chief Scientific Officer | F | −26,657 | −$81.04K |
| 2026-05-19 | Christopher Gibson | Director | F | −22,821 | −$69.38K |
| 2026-05-08 | Christopher Gibson | Director | MIXED | — | −$134.80K |
| 2026-05-07 | Blake Borgeson | Director | Sell | −30,000 | −$105.60K |
| 2026-04-24 | Christopher Gibson | Director | MIXED | — | −$144.40K |
| 2026-04-08 | Blake Borgeson | Director | Sell | −30,000 | −$93.00K |
| 2026-04-08 | Ben R Taylor | Chief Financial Officer | F | −48,028 | −$149.37K |
| 2026-04-08 | Christopher Gibson | Director | MIXED | — | −$124.00K |
| 2026-04-02 | Zavain Dar | Director | A | +4,902 | — |
| 2026-04-02 | Dean Y Li | Director | A | +3,268 | — |
| 2026-03-25 | Christopher Gibson | Director | MIXED | — | −$130.00K |
| 2026-03-18 | Ben R Taylor | Chief Financial Officer | MIXED | −15,031 | −$51.17K |
| 2026-03-11 | Najat Khan | CEO and President | Sell | −28,298 | −$94.66K |
| 2026-03-11 | Christopher Gibson | Director | MIXED | — | — |
| 2026-03-04 | Blake Borgeson | Director | Sell | −170,000 | −$588.20K |
| 2026-02-19 | Ben R Taylor | Chief Financial Officer | MIXED | −25,334 | −$82.91K |
| 2026-02-19 | Najat Khan | CEO and President | F | −14,280 | −$49.84K |
| 2026-02-19 | David Hallett | Chief Scientific Officer | F | −11,908 | −$41.56K |
| 2026-02-19 | Christopher Gibson | Director | MIXED | −27,265 | −$233.55K |
| 2026-02-10 | Ben R Taylor | Chief Financial Officer | MIXED | +459,133 | −$45.37K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Blake Borgeson | Director | 6,108,287 | $26.63M |
| Najat Khan | CEO and President | 2,072,890 | $9.04M |
| Dean Y Li | Director | 1,897,707 | $8.27M |
| Michael Secora | Chief Financial Officer | 1,487,694 | $6.49M |
| Ben R Taylor | Chief Financial Officer | 1,071,462 | $4.67M |
| David Hallett | Chief Scientific Officer | 1,043,837 | $4.55M |
| Christopher Gibson | Director | 901,610 | $3.93M |
| Tina Marriott | President and COO | 506,852 | $2.21M |
| Zavain Dar | Director | 245,371 | $1.07M |
| David J Mauro | Chief Medical Officer | 225,429 | $982.87K |
| Franziska Michor | Director | 215,477 | $939.48K |
| Robert Hershberg | Director | 187,156 | $816.00K |
| Elaine D Sun | Director | 135,981 | $592.88K |
| Namandje Bumpus | Director | 131,595 | $573.75K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RXRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.